Last reviewed · How we verify

MB 6 doses - Rifampicin, Clofazimine and Dapsone

University of Brasilia · FDA-approved active Small molecule Quality 2/100

MB 6 doses - Rifampicin, Clofazimine and Dapsone is a Small molecule drug developed by University of Brasilia. It is currently FDA-approved. Also known as: MB 6 doses of 3 drugs.

At a glance

Generic nameMB 6 doses - Rifampicin, Clofazimine and Dapsone
Also known asMB 6 doses of 3 drugs
SponsorUniversity of Brasilia
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about MB 6 doses - Rifampicin, Clofazimine and Dapsone

What is MB 6 doses - Rifampicin, Clofazimine and Dapsone?

MB 6 doses - Rifampicin, Clofazimine and Dapsone is a Small molecule drug developed by University of Brasilia.

Who makes MB 6 doses - Rifampicin, Clofazimine and Dapsone?

MB 6 doses - Rifampicin, Clofazimine and Dapsone is developed and marketed by University of Brasilia (see full University of Brasilia pipeline at /company/university-of-brasilia).

Is MB 6 doses - Rifampicin, Clofazimine and Dapsone also known as anything else?

MB 6 doses - Rifampicin, Clofazimine and Dapsone is also known as MB 6 doses of 3 drugs.

What development phase is MB 6 doses - Rifampicin, Clofazimine and Dapsone in?

MB 6 doses - Rifampicin, Clofazimine and Dapsone is FDA-approved (marketed).

Related